Clinical Trial Announcement: Rapport Therapeutics Inc. will report topline results from its phase IIa trial of RAP-219 for drug-resistant focal onset seizures on September 8, 2025, during a conference call at 8:00 am ET.
Trial Objectives and Metrics: The trial's primary endpoint will assess the reduction in localized events during treatment, while secondary endpoints will evaluate the reduction in clinical seizures and the incidence of treatment-emergent adverse events.
RAPP
$30.76+Infinity%1D
Analyst Views on RAPP
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 53.00 USD with a low forecast of 34.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 53.00 USD with a low forecast of 34.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.600
Low
34.00
Averages
53.00
High
80.00
Current: 29.600
Low
34.00
Averages
53.00
High
80.00
BTIG
NULL -> Buy
initiated
$47
2025-11-18
Reason
BTIG
Price Target
$47
2025-11-18
initiated
NULL -> Buy
Reason
BTIG initiated coverage of Rapport Therapeutics with a Buy rating and $47 price target. Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions, the analyst tells investors in a research note. BTIG has a high degree of confidence that the Phase 3 registrational focal epilepsy trials for RAP-219 will be successful and that the drug will receive approval.
Citizens JMP
Outperform
maintain
$77 -> $80
2025-11-07
Reason
Citizens JMP
Price Target
$77 -> $80
2025-11-07
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Rapport Therapeutics to $80 from $77 and keeps an Outperform rating on the shares. Rapport reported Q3 results and said it continues to advance RAP-219 development, the analyst tells investors in a research note. The firm continues to believe that the results from the Phase 2a proof-of-concept study evaluating RAP-219 in focal epilepsy can be rapidly and broadly adopted in clinical practice.
Truist
Joon Lee
Buy
initiated
$44
2025-09-16
Reason
Truist
Joon Lee
Price Target
$44
2025-09-16
initiated
Buy
Reason
Truist analyst Joon Lee initiated coverage of Rapport Therapeutics with a Buy rating and $44 price target. Rapport is focused on the central nervous system with a lead program in focal onset epilepsy, a therapeutic area worth $10B annually and growing, the analyst tells investors in a research note. The firm believes RAP-219's magnitude and speed of seizure reduction is "impressive" and models over$1B in peak sales in 2038 for focal onset epilepsy alone.
Goldman Sachs
Salveen Richter
maintain
$51
2025-09-12
Reason
Goldman Sachs
Salveen Richter
Price Target
$51
2025-09-12
maintain
Reason
Goldman Sachs analyst Salveen Richter assigned Rapport Therapeutics with a Buy rating and $51 price target from its Early-Stage Biotech designation. RAP-219's Phase 2 epilepsy data showed a 71% reduction in long episodes, the primary endpoint, with 24% achieving seizure freedom for the eight-week treatment period, the analyst tells investors in a research note. Goldman now views RAP-219 as well-positioned into the Phase 3 study given the Phase 2 "de-risking."
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
